LentiArray™ Cas9 Lentivirus
본 제품은 LMO 제품으로, 고객 분께서 LMO 신고 시스템을 통해 직접 수입 신고를 진행해주셔야 합니다. 자세히보기
Product Image
Invitrogen™

LentiArray™ Cas9 Lentivirus

LentiArray Cas9 Lentivirus is provided as high-titer purified lentiviral particles and is an efficient method to drive high level Cas9 nuclease expression in a wide variety of cell types.
Have Questions?
카탈로그 번호수량
A320691 mL
카탈로그 번호 A32069
제품 가격(KRW)
3,296,000
Each
카트에 추가하기
수량:
1 mL
제품 가격(KRW)
3,296,000
Each
카트에 추가하기

The LentiArray Cas9 Lentivirus construct includes a human codon-optimized version of Cas9 with two nuclear localization signals to facilitate efficient delivery into the nucleus. The 1-mL size is designed to support studies utilizing a co-infection approach (Cas9 lentivirus + guideRNA lentivirus delivered together) with either the LentiArray CRISPR libraries or LentiArray gRNAs against single gene targets. LentiArray Cas9 Lentivirus is provided as ready-to-use lentivirus at a titer of 1 x 107 TU/mL.

Features include:

  • 1 mL high-titer lentiviral particles
  • Ready-to-use lentiviral particles at a titer of 1 x 107 TU/mL
  • EF-1a promotor that is highly effective in a wide variety of cell models
  • Create stable Cas9-expressing cell models for screening and focused CRISPR knockout studies
For Research Use Only. Not for use in diagnostic procedures.
사양
배달 유형Lentiviral
용도(애플리케이션)CRISPR gene knockout
제품라인LentiArray
제품 유형Cas9 Lentivirus
수량1 mL
배송 조건Dry Ice
프로모터EF-1a
샘플 종류siRNA
Human
Transfection TechniqueLentiviral transduction
Unit SizeEach
구성 및 보관
1 x 1 mL. Store at -68 to -85°C.

인용 및 참조 문헌 (1)

인용 및 참조 문헌
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More